+357 96 030922
info@marketpublishers.com

Global Non-Opioid Pain Drug Supply, Demand and Key Producers, 2026-2032

https://marketpublishers.com/r/G2CE4C17E7D4EN.html
Date: September 2026
Pages: 157
Price: US$ 4,480.00 (Single User License)
ID: G2CE4C17E7D4EN

Abstracts

The global Non-Opioid Pain Drug market size is expected to reach $ 58915 million by 2032, rising at a market growth of 4.4% CAGR during the forecast period (2026-2032).

Non-Opioid Pain Drug refers to pharmaceutical products that provide analgesic effects without relying on opioid receptor agonism as their primary pain-relief mechanism. The market covers a broad therapeutic spectrum ranging from established systemic analgesics to newer mechanism-specific and site-directed therapies, with major product categories including acetaminophen/paracetamol, nonsteroidal anti-inflammatory drugs (NSAIDs), selective COX-2 inhibitors, sodium channel pain signal inhibitors, local anesthetic analgesics, capsaicin-based analgesics, anticonvulsant analgesics, antidepressant analgesics and other non-opioid therapies. Products are commercialized as single-agent or combination drugs, across prescription and over-the-counter channels, and in oral, injectable, topical, transdermal and other formulations. The principal clinical applications include postoperative pain, musculoskeletal pain, arthritis pain, neuropathic pain, headache and migraine, dental pain, back pain, menstrual pain, injury and trauma pain, and selected cancer-related pain settings. The research focus therefore spans both high-volume routine pain management and differentiated prescription therapies designed for more targeted, prolonged or opioid-sparing analgesia.

Key Findings

The average gross profit margin of this product is 45%

NSAIDs and acetaminophen remain the broadest treatment foundation across

+357 96 030922
info@marketpublishers.com

pain care

Prescription innovation increasingly targets peripheral pain signaling without opioid receptor activation

Postoperative pain is a strategic field for long acting local analgesia

Oral drugs anchor routine use while topical formats widen treatment access

Competition spans consumer health specialty pharma and broad generic portfolios

Market Trends

The Non-Opioid Pain Drug market is moving from a structure dominated primarily by conventional systemic analgesics toward a more diversified treatment model combining established drugs, mechanism-targeted therapies, localized delivery and multimodal pain management. NSAIDs and acetaminophen continue to underpin routine acute and musculoskeletal pain treatment, while innovation is increasingly focused on improving analgesic selectivity, duration of action and site specificity. The U.S. FDA approval of suzetrigine in 2025 introduced a new class of oral non-opioid analgesia targeting peripheral sodium-channel-mediated pain signaling, illustrating the industry's growing interest in treating pain before signals reach central pathways. At the same time, prolonged local anesthetic formulations and dual-mechanism perioperative therapies are broadening the role of non-opioid drugs in postoperative pain management. Consumer pain-care products are also evolving through differentiated release profiles, topical formulations and fixed-dose combinations. The long-term direction of the market is therefore shifting from simply replacing opioids with conventional analgesics toward matching different pain mechanisms, treatment durations and clinical scenarios with more specialized non-opioid options.

Market Dynamics

Drivers

Demand for Non-Opioid Pain Drug products is supported by the persistent clinical burden of acute and chronic pain and by efforts to minimize unnecessary opioid

+357 96 030922
info@marketpublishers.com

exposure where effective alternatives are available. Non-opioid therapies already play an established role in common acute pain conditions, including musculoskeletal injuries, back pain and minor procedural pain, while acetaminophen, oral and topical NSAIDs and other non-opioid medicines remain widely integrated into routine treatment pathways. Clinical practice is increasingly emphasizing treatment selection according to pain type, expected duration, patient risk factors and functional goals rather than relying on a single analgesic class. This creates a broad demand base covering both consumer self-care products and prescription therapies. Perioperative care represents an additional driver as hospitals and clinicians increasingly use multimodal analgesic strategies combining systemic medicines with long-acting or site-specific local therapies to improve pain control while reducing reliance on opioid rescue medication.

Restraints

The principal limitation of the Non-Opioid Pain Drug market is that non-opioid does not mean clinically unrestricted. Established drug classes have well-defined dosing, contraindication and tolerability considerations that limit their use in particular patient populations. NSAIDs, for example, are associated with gastrointestinal and cardiovascular risks that become particularly relevant in older patients, patients with underlying disease and prolonged treatment settings. Other therapeutic classes similarly require patient-specific assessment and may not provide adequate analgesia for every pain severity or mechanism. At the commercial level, many traditional non-opioid analgesics are mature and highly genericized, creating strong price competition and limiting differentiation for standard formulations. Conversely, newer proprietary therapies may face higher treatment costs, reimbursement scrutiny and formulary barriers. The market consequently operates between two pressures: commoditization in established drug classes and the need for newer therapies to demonstrate sufficient clinical and economic value to justify premium positioning.

Opportunities

The most important opportunity lies in expanding the therapeutic space between conventional first-line analgesics and opioid therapy. Mechanism-specific oral medicines, prolonged local anesthetics, topical and transdermal therapies and rational combination products provide multiple routes for companies to address this gap. Acute moderate-to-severe pain is becoming particularly important because successful non-opioid products can potentially participate in treatment settings historically associated with substantial opioid use. The emergence of peripheral sodium channel pain signal

+357 96 030922
info@marketpublishers.com

inhibition demonstrates the potential for fundamentally new analgesic mechanisms, while extended-duration local therapies create opportunities in surgery and procedure-related pain. Additional opportunities exist in neuropathic pain, musculoskeletal disorders and targeted topical treatment, where patient heterogeneity favors differentiated therapeutic approaches. Combination products also offer potential to improve onset, duration or multimodal efficacy without relying on opioid components, supporting continued product reformulation and lifecycle innovation across both prescription and consumer-health markets.

Challenges

A central challenge for the Non-Opioid Pain Drug industry is translating pharmacological innovation into clinically meaningful advantages across highly heterogeneous pain conditions. Pain intensity is subjective, treatment response differs substantially among patients, and acute, inflammatory, neuropathic and postoperative pain involve different biological mechanisms. A therapy that performs well in one setting therefore cannot automatically establish broad value across the entire pain market. New prescription products must demonstrate not only statistically significant pain reduction but also clinically relevant improvements in duration, tolerability, functional recovery, opioid-sparing potential or ease of use. Companies must then secure reimbursement, hospital formulary access, physician adoption and patient acceptance while competing against inexpensive generic analgesics. Long development timelines and demanding clinical endpoints further increase commercialization risk. As the number of non-opioid approaches expands, differentiation will increasingly depend on clearly identifying the pain population, treatment setting and clinical value proposition in which each therapy provides a meaningful advantage.

Industry Chain Analysis

The upstream portion of the Non-Opioid Pain Drug industry consists primarily of active pharmaceutical ingredients, pharmaceutical intermediates, excipients and specialized formulation or drug-delivery materials. Conventional oral analgesics rely heavily on mature API manufacturing and large-scale solid-dose production, making manufacturing efficiency, quality control and supply security important competitive factors. More differentiated products introduce additional technical requirements, including sustained-release technologies, liposomal delivery systems, transdermal matrices, topical penetration systems and specialized injectable formulations. These technologies

+357 96 030922
info@marketpublishers.com

increase formulation complexity and can shift value creation away from the active ingredient alone toward proprietary delivery platforms, manufacturing know-how and intellectual property.

The midstream encompasses formulation development, clinical development, regulatory approval, commercial manufacturing, brand management and lifecycle management. Downstream channels differ significantly by product positioning: over-the-counter analgesics depend heavily on pharmacies, retail and consumer-health distribution, while prescription products rely more strongly on hospitals, physicians, specialty pharmacy and institutional formularies. In postoperative applications, adoption is closely linked to surgical protocols and hospital pain-management pathways. The value chain is therefore bifurcated. Mature generic products derive competitive advantage from manufacturing scale, procurement efficiency and channel coverage, whereas innovative non-opioid therapies capture value through differentiated mechanisms, longer duration of action, targeted delivery, clinical evidence and intellectual-property protection.

Segment Insights

From a Type perspective, acetaminophen/paracetamol and NSAIDs represent the broadest foundation of the Non-Opioid Pain Drug market because of their established role across common acute, inflammatory, dental, musculoskeletal and self-treated pain. Selective COX-2 inhibitors occupy a more differentiated anti-inflammatory position, while local anesthetic analgesics have particular relevance in procedural and postoperative settings. Sodium channel pain signal inhibitors represent an emerging mechanism-oriented segment following the introduction of a first-in-class therapy for moderate-to-severe acute pain. Capsaicin-based products, anticonvulsant analgesics and antidepressant analgesics address more specialized pain mechanisms, particularly neuropathic and chronic pain conditions. The market is consequently becoming more segmented by pain biology rather than being defined only by analgesic strength.

Across Class, Group and Sort, single-agent drugs continue to provide the core treatment base, while combination products offer opportunities for complementary mechanisms and differentiated duration or onset of action. Prescription products are particularly important where pain severity, comorbidity or specialized delivery requires physician supervision, whereas OTC medicines remain central to everyday pain self-management. Oral formulations provide the widest routine-use platform, but injectable, topical and transdermal products allow treatment to become more site-specific and can address patients or clinical scenarios where systemic exposure is less desirable. The

+357 96 030922
info@marketpublishers.com

development of prolonged local analgesia and increasingly differentiated topical pain products suggests that formulation technology is becoming an important source of competitive separation alongside active pharmaceutical innovation.

Downstream Market Opportunities

Downstream demand for Non-Opioid Pain Drug products spans everyday self-treated pain and highly managed clinical pain pathways. Musculoskeletal pain, arthritis, back pain, headache and migraine, dental pain and menstrual pain provide recurring demand for accessible oral and topical products, while neuropathic pain requires more mechanism-specific pharmacotherapy. Postoperative pain represents one of the most strategically important opportunities because treatment decisions occur within structured hospital and surgical protocols where duration of analgesia, recovery quality and opioid-sparing potential can materially influence product selection. Injury and trauma pain also support short-term acute treatment demand, while selected cancer-related pain settings create opportunities for non-opioid medicines as components of multimodal therapy. The major commercial opportunity is therefore not a single application, but the progressive segmentation of pain management according to etiology, severity, duration and treatment setting.

Regional Insights

North America is an important innovation and commercialization market for Non-Opioid Pain Drug products, particularly for novel prescription mechanisms and perioperative pain-management therapies. Recent regulatory progress in peripheral sodium channel inhibition and continued development of extended-duration local analgesics demonstrate active efforts to broaden non-opioid treatment options in acute and postoperative pain. The region also has a mature consumer-health market supported by established OTC analgesic brands. Europe similarly represents a mature market, with significant use of both prescription and OTC pain medicines and opportunities centered on formulation differentiation, localized pain treatment and improved patient selection.

Asia-Pacific combines a large base of conventional analgesic use with expanding demand for branded OTC products, prescription pain management and differentiated formulations. Japan has a well-developed topical and transdermal pain-treatment tradition, while China combines large-scale generic pharmaceutical manufacturing with increasing development of innovative and higher-value prescription therapies. Across

+357 96 030922
info@marketpublishers.com

emerging markets, affordability and broad distribution remain critical, meaning established oral drugs are likely to retain substantial importance even as more specialized products expand. Regional competition will therefore remain structurally different: innovation and premium prescription therapies are more prominent in developed markets, while manufacturing economics, accessibility and channel penetration remain especially influential in price-sensitive markets.

Competitive Landscape Analysis

The competitive landscape is structurally diversified rather than dominated by one type of pharmaceutical company. Within the confirmed company set, Kenvue, Haleon and Bayer participate strongly through established consumer pain-care portfolios, while Vertex Pharmaceuticals Incorporated, Pfizer Inc., Pacira BioSciences, Inc., Heron Therapeutics, Inc., Scilex Holding Company and Grünenthal GmbH represent prescription or specialty-pharma approaches to differentiated pain management. Hisamitsu Pharmaceutical Co., Inc., Daiichi Sankyo Healthcare Co., Ltd. and AFT Pharmaceuticals Limited add regional and formulation-focused positions, while Viatris Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd. and Sun Pharmaceutical Industries Ltd. participate through broad pharmaceutical portfolios and large-scale manufacturing capabilities; Jiangsu Hengrui Pharmaceuticals Co., Ltd. represents the confirmed Chinese participant in the research scope. Competition therefore occurs across several dimensions simultaneously: consumer brand recognition, manufacturing scale, prescription access, formulation technology, proprietary mechanisms, clinical evidence and distribution reach. Recent progress in selective peripheral pain signaling and prolonged local analgesia indicates that future competitive differentiation is likely to rely increasingly on mechanism specificity and demonstrable clinical value rather than simple expansion of conventional analgesic portfolios.

Report Scope

This report studies the global Non-Opioid Pain Drug demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Non-Opioid Pain Drug, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and

+357 96 030922
info@marketpublishers.com

competition, as well as details the characteristics of Non-Opioid Pain Drug that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Non-Opioid Pain Drug total market, 2021-2032, (USD Million)

Global Non-Opioid Pain Drug total market by region & country, CAGR, 2021-2032, (USD Million)

U.S. VS China: Non-Opioid Pain Drug total market, key domestic companies, and share, (USD Million)

Global Non-Opioid Pain Drug revenue by player, revenue and market share 2021-2026, (USD Million)

Global Non-Opioid Pain Drug total market by Type, CAGR, 2021-2032, (USD Million)

Global Non-Opioid Pain Drug total market by Application, CAGR, 2021-2032, (USD Million)

This report profiles major players in the global Non-Opioid Pain Drug market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Vertex Pharmaceuticals, Kenvue, Haleon, Bayer, Pfizer, Pacira BioSciences, Heron Therapeutics, Scilex Holding, Grünenthal, Hisamitsu Pharmaceutical, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Non-Opioid Pain Drug market

+357 96 030922
info@marketpublishers.com

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global Non-Opioid Pain Drug Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Market Segmentation

Global Non-Opioid Pain Drug Market, Segmentation by Type:

Acetaminophen/Paracetamol

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

Selective COX-2 Inhibitors

Sodium Channel Pain Signal Inhibitors

+357 96 030922
info@marketpublishers.com

Local Anesthetic Analgesics

Other

Global Non-Opioid Pain Drug Market, Segmentation by Drug Ingredients:

Single-Agent Drugs

Combination Drugs

Global Non-Opioid Pain Drug Market, Segmentation by Route of Administration:

Oral Drugs

Injectable Drugs

Topical Drugs

Global Non-Opioid Pain Drug Market, Segmentation by Application:

Postoperative Pain

Musculoskeletal Pain

Arthritis Pain

Neuropathic Pain

Headache and Migraine

Other

+357 96 030922
info@marketpublishers.com

Companies Profiled:

Vertex Pharmaceuticals

Kenvue

Haleon

Bayer

Pfizer

Pacira BioSciences

Heron Therapeutics

Scilex Holding

Grünenthal

Hisamitsu Pharmaceutical

Daiichi Sankyo

AFT Pharmaceuticals

Viatris

Teva Pharmaceutical

Dr. Reddy's

Sun Pharmaceutical

Jiangsu Hengrui

Johnson & Johnson

+357 96 030922
info@marketpublishers.com

Hubei Hendi Pharmaceutical

CSPC Pharmaceutical Group

Simcere Pharmaceutical

Qilu Pharmaceutical

Yichang Humanwell Pharmaceutical

Tongfang Pharma

Fresenius

Key Questions Answered

1. How big is the global Non-Opioid Pain Drug market?
2. What is the demand of the global Non-Opioid Pain Drug market?
3. What is the year over year growth of the global Non-Opioid Pain Drug market?
4. What is the total value of the global Non-Opioid Pain Drug market?
5. Who are the Major Players in the global Non-Opioid Pain Drug market?
6. What are the growth factors driving the market demand?

+357 96 030922
info@marketpublishers.com

Contents

1 SUPPLY SUMMARY

1.1 Non-Opioid Pain Drug Introduction
1.2 World Non-Opioid Pain Drug Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Non-Opioid Pain Drug Total Market by Region (by Headquarter Location)
  1.3.1 World Non-Opioid Pain Drug Market Size by Region (2021-2032), (by Headquarter Location)
  1.3.2 United States Based Company Non-Opioid Pain Drug Revenue (2021-2032)
  1.3.3 China Based Company Non-Opioid Pain Drug Revenue (2021-2032)
  1.3.4 Europe Based Company Non-Opioid Pain Drug Revenue (2021-2032)
  1.3.5 Japan Based Company Non-Opioid Pain Drug Revenue (2021-2032)
  1.3.6 South Korea Based Company Non-Opioid Pain Drug Revenue (2021-2032)
  1.3.7 ASEAN Based Company Non-Opioid Pain Drug Revenue (2021-2032)
  1.3.8 India Based Company Non-Opioid Pain Drug Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
  1.4.1 Non-Opioid Pain Drug Market Drivers
  1.4.2 Factors Affecting Demand
  1.4.3 Major Market Trends

2 DEMAND SUMMARY

2.1 World Non-Opioid Pain Drug Consumption Value (2021-2032)
2.2 World Non-Opioid Pain Drug Consumption Value by Region
  2.2.1 World Non-Opioid Pain Drug Consumption Value by Region (2021-2026)
  2.2.2 World Non-Opioid Pain Drug Consumption Value Forecast by Region (2027-2032)
2.3 United States Non-Opioid Pain Drug Consumption Value (2021-2032)
2.4 China Non-Opioid Pain Drug Consumption Value (2021-2032)
2.5 Europe Non-Opioid Pain Drug Consumption Value (2021-2032)
2.6 Japan Non-Opioid Pain Drug Consumption Value (2021-2032)
2.7 South Korea Non-Opioid Pain Drug Consumption Value (2021-2032)
2.8 ASEAN Non-Opioid Pain Drug Consumption Value (2021-2032)
2.9 India Non-Opioid Pain Drug Consumption Value (2021-2032)

3 WORLD NON-OPIOID PAIN DRUG COMPANIES COMPETITIVE ANALYSIS

3.1 World Non-Opioid Pain Drug Revenue by Player (2021-2026)

+357 96 030922
info@marketpublishers.com

3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Non-Opioid Pain Drug Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Non-Opioid Pain Drug in 2025
3.2.3 Global Concentration Ratios (CR8) for Non-Opioid Pain Drug in 2025
3.3 Non-Opioid Pain Drug Company Evaluation Quadrant
3.4 Non-Opioid Pain Drug Market: Overall Company Footprint Analysis
3.4.1 Non-Opioid Pain Drug Market: Region Footprint
3.4.2 Non-Opioid Pain Drug Market: Company Product Type Footprint
3.4.3 Non-Opioid Pain Drug Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity

4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)

4.1 United States VS China: Non-Opioid Pain Drug Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Non-Opioid Pain Drug Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Non-Opioid Pain Drug Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Non-Opioid Pain Drug Consumption Value Comparison
4.2.1 United States VS China: Non-Opioid Pain Drug Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Non-Opioid Pain Drug Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Non-Opioid Pain Drug Companies and Market Share, 2021-2026
4.3.1 United States Based Non-Opioid Pain Drug Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Non-Opioid Pain Drug Revenue, (2021-2026)
4.4 China Based Companies Non-Opioid Pain Drug Revenue and Market Share, 2021-2026
4.4.1 China Based Non-Opioid Pain Drug Companies, Company Headquarters (Province, Country)

+357 96 030922
info@marketpublishers.com

4.4.2 China Based Companies Non-Opioid Pain Drug Revenue, (2021-2026)
4.5 Rest of World Based Non-Opioid Pain Drug Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Non-Opioid Pain Drug Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Non-Opioid Pain Drug Revenue (2021-2026)

5 MARKET ANALYSIS BY TYPE

5.1 World Non-Opioid Pain Drug Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Acetaminophen/Paracetamol
5.2.2 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
5.2.3 Selective COX-2 Inhibitors
5.2.4 Sodium Channel Pain Signal Inhibitors
5.2.5 Local Anesthetic Analgesics
5.2.6 Other
5.3 Market Segment by Type
5.3.1 World Non-Opioid Pain Drug Market Size by Type (2021-2026)
5.3.2 World Non-Opioid Pain Drug Market Size by Type (2027-2032)
5.3.3 World Non-Opioid Pain Drug Market Size Market Share by Type (2027-2032)

6 MARKET ANALYSIS BY DRUG INGREDIENTS

6.1 World Non-Opioid Pain Drug Market Size Overview by Drug Ingredients: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Drug Ingredients
6.2.1 Single-Agent Drugs
6.2.2 Combination Drugs
6.3 Market Segment by Drug Ingredients
6.3.1 World Non-Opioid Pain Drug Market Size by Drug Ingredients (2021-2026)
6.3.2 World Non-Opioid Pain Drug Market Size by Drug Ingredients (2027-2032)
6.3.3 World Non-Opioid Pain Drug Market Size Market Share by Drug Ingredients (2027-2032)

7 MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

7.1 World Non-Opioid Pain Drug Market Size Overview by Route of Administration:

+357 96 030922
info@marketpublishers.com

2021 VS 2025 VS 2032
7.2 Segment Introduction by Route of Administration
7.2.1 Oral Drugs
7.2.2 Injectable Drugs
7.2.3 Topical Drugs
7.3 Market Segment by Route of Administration
7.3.1 World Non-Opioid Pain Drug Market Size by Route of Administration (2021-2026)
7.3.2 World Non-Opioid Pain Drug Market Size by Route of Administration (2027-2032)
7.3.3 World Non-Opioid Pain Drug Market Size Market Share by Route of Administration (2027-2032)

8 MARKET ANALYSIS BY APPLICATION

8.1 World Non-Opioid Pain Drug Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Postoperative Pain
8.2.2 Musculoskeletal Pain
8.2.3 Arthritis Pain
8.2.4 Neuropathic Pain
8.2.5 Headache and Migraine
8.2.6 Other
8.3 Market Segment by Application
8.3.1 World Non-Opioid Pain Drug Market Size by Application (2021-2026)
8.3.2 World Non-Opioid Pain Drug Market Size by Application (2027-2032)
8.3.3 World Non-Opioid Pain Drug Market Size Market Share by Application (2021-2032)

9 COMPANY PROFILES

9.1 Vertex Pharmaceuticals
9.1.1 Vertex Pharmaceuticals Details
9.1.2 Vertex Pharmaceuticals Major Business
9.1.3 Vertex Pharmaceuticals Non-Opioid Pain Drug Product and Services
9.1.4 Vertex Pharmaceuticals Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Vertex Pharmaceuticals Recent Developments/Updates

+357 96 030922
info@marketpublishers.com

9.1.6 Vertex Pharmaceuticals Competitive Strengths & Weaknesses
9.2 Kenvue
9.2.1 Kenvue Details
9.2.2 Kenvue Major Business
9.2.3 Kenvue Non-Opioid Pain Drug Product and Services
9.2.4 Kenvue Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Kenvue Recent Developments/Updates
9.2.6 Kenvue Competitive Strengths & Weaknesses
9.3 Haleon
9.3.1 Haleon Details
9.3.2 Haleon Major Business
9.3.3 Haleon Non-Opioid Pain Drug Product and Services
9.3.4 Haleon Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Haleon Recent Developments/Updates
9.3.6 Haleon Competitive Strengths & Weaknesses
9.4 Bayer
9.4.1 Bayer Details
9.4.2 Bayer Major Business
9.4.3 Bayer Non-Opioid Pain Drug Product and Services
9.4.4 Bayer Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 Bayer Recent Developments/Updates
9.4.6 Bayer Competitive Strengths & Weaknesses
9.5 Pfizer
9.5.1 Pfizer Details
9.5.2 Pfizer Major Business
9.5.3 Pfizer Non-Opioid Pain Drug Product and Services
9.5.4 Pfizer Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 Pfizer Recent Developments/Updates
9.5.6 Pfizer Competitive Strengths & Weaknesses
9.6 Pacira BioSciences
9.6.1 Pacira BioSciences Details
9.6.2 Pacira BioSciences Major Business
9.6.3 Pacira BioSciences Non-Opioid Pain Drug Product and Services
9.6.4 Pacira BioSciences Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)

+357 96 030922
info@marketpublishers.com

9.6.5 Pacira BioSciences Recent Developments/Updates
9.6.6 Pacira BioSciences Competitive Strengths & Weaknesses
9.7 Heron Therapeutics
9.7.1 Heron Therapeutics Details
9.7.2 Heron Therapeutics Major Business
9.7.3 Heron Therapeutics Non-Opioid Pain Drug Product and Services
9.7.4 Heron Therapeutics Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 Heron Therapeutics Recent Developments/Updates
9.7.6 Heron Therapeutics Competitive Strengths & Weaknesses
9.8 Scilex Holding
9.8.1 Scilex Holding Details
9.8.2 Scilex Holding Major Business
9.8.3 Scilex Holding Non-Opioid Pain Drug Product and Services
9.8.4 Scilex Holding Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Scilex Holding Recent Developments/Updates
9.8.6 Scilex Holding Competitive Strengths & Weaknesses
9.9 Grünenthal
9.9.1 Grünenthal Details
9.9.2 Grünenthal Major Business
9.9.3 Grünenthal Non-Opioid Pain Drug Product and Services
9.9.4 Grünenthal Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 Grünenthal Recent Developments/Updates
9.9.6 Grünenthal Competitive Strengths & Weaknesses
9.10 Hisamitsu Pharmaceutical
9.10.1 Hisamitsu Pharmaceutical Details
9.10.2 Hisamitsu Pharmaceutical Major Business
9.10.3 Hisamitsu Pharmaceutical Non-Opioid Pain Drug Product and Services
9.10.4 Hisamitsu Pharmaceutical Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 Hisamitsu Pharmaceutical Recent Developments/Updates
9.10.6 Hisamitsu Pharmaceutical Competitive Strengths & Weaknesses
9.11 Daiichi Sankyo
9.11.1 Daiichi Sankyo Details
9.11.2 Daiichi Sankyo Major Business
9.11.3 Daiichi Sankyo Non-Opioid Pain Drug Product and Services
9.11.4 Daiichi Sankyo Non-Opioid Pain Drug Revenue, Gross Margin and Market

+357 96 030922
info@marketpublishers.com

Share (2021-2026)
9.11.5 Daiichi Sankyo Recent Developments/Updates
9.11.6 Daiichi Sankyo Competitive Strengths & Weaknesses
9.12 AFT Pharmaceuticals
9.12.1 AFT Pharmaceuticals Details
9.12.2 AFT Pharmaceuticals Major Business
9.12.3 AFT Pharmaceuticals Non-Opioid Pain Drug Product and Services
9.12.4 AFT Pharmaceuticals Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
9.12.5 AFT Pharmaceuticals Recent Developments/Updates
9.12.6 AFT Pharmaceuticals Competitive Strengths & Weaknesses
9.13 Viatris
9.13.1 Viatris Details
9.13.2 Viatris Major Business
9.13.3 Viatris Non-Opioid Pain Drug Product and Services
9.13.4 Viatris Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
9.13.5 Viatris Recent Developments/Updates
9.13.6 Viatris Competitive Strengths & Weaknesses
9.14 Teva Pharmaceutical
9.14.1 Teva Pharmaceutical Details
9.14.2 Teva Pharmaceutical Major Business
9.14.3 Teva Pharmaceutical Non-Opioid Pain Drug Product and Services
9.14.4 Teva Pharmaceutical Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
9.14.5 Teva Pharmaceutical Recent Developments/Updates
9.14.6 Teva Pharmaceutical Competitive Strengths & Weaknesses
9.15 Dr. Reddy's
9.15.1 Dr. Reddy's Details
9.15.2 Dr. Reddy's Major Business
9.15.3 Dr. Reddy's Non-Opioid Pain Drug Product and Services
9.15.4 Dr. Reddy's Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
9.15.5 Dr. Reddy's Recent Developments/Updates
9.15.6 Dr. Reddy's Competitive Strengths & Weaknesses
9.16 Sun Pharmaceutical
9.16.1 Sun Pharmaceutical Details
9.16.2 Sun Pharmaceutical Major Business
9.16.3 Sun Pharmaceutical Non-Opioid Pain Drug Product and Services

+357 96 030922
info@marketpublishers.com

9.16.4 Sun Pharmaceutical Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
9.16.5 Sun Pharmaceutical Recent Developments/Updates
9.16.6 Sun Pharmaceutical Competitive Strengths & Weaknesses
9.17 Jiangsu Hengrui
9.17.1 Jiangsu Hengrui Details
9.17.2 Jiangsu Hengrui Major Business
9.17.3 Jiangsu Hengrui Non-Opioid Pain Drug Product and Services
9.17.4 Jiangsu Hengrui Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
9.17.5 Jiangsu Hengrui Recent Developments/Updates
9.17.6 Jiangsu Hengrui Competitive Strengths & Weaknesses
9.18 Johnson & Johnson
9.18.1 Johnson & Johnson Details
9.18.2 Johnson & Johnson Major Business
9.18.3 Johnson & Johnson Non-Opioid Pain Drug Product and Services
9.18.4 Johnson & Johnson Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
9.18.5 Johnson & Johnson Recent Developments/Updates
9.18.6 Johnson & Johnson Competitive Strengths & Weaknesses
9.19 Hubei Hendi Pharmaceutical
9.19.1 Hubei Hendi Pharmaceutical Details
9.19.2 Hubei Hendi Pharmaceutical Major Business
9.19.3 Hubei Hendi Pharmaceutical Non-Opioid Pain Drug Product and Services
9.19.4 Hubei Hendi Pharmaceutical Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
9.19.5 Hubei Hendi Pharmaceutical Recent Developments/Updates
9.19.6 Hubei Hendi Pharmaceutical Competitive Strengths & Weaknesses
9.20 CSPC Pharmaceutical Group
9.20.1 CSPC Pharmaceutical Group Details
9.20.2 CSPC Pharmaceutical Group Major Business
9.20.3 CSPC Pharmaceutical Group Non-Opioid Pain Drug Product and Services
9.20.4 CSPC Pharmaceutical Group Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
9.20.5 CSPC Pharmaceutical Group Recent Developments/Updates
9.20.6 CSPC Pharmaceutical Group Competitive Strengths & Weaknesses
9.21 Simcere Pharmaceutical
9.21.1 Simcere Pharmaceutical Details
9.21.2 Simcere Pharmaceutical Major Business

+357 96 030922
info@marketpublishers.com

9.21.3 Simcere Pharmaceutical Non-Opioid Pain Drug Product and Services
9.21.4 Simcere Pharmaceutical Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
9.21.5 Simcere Pharmaceutical Recent Developments/Updates
9.21.6 Simcere Pharmaceutical Competitive Strengths & Weaknesses
9.22 Qilu Pharmaceutical
9.22.1 Qilu Pharmaceutical Details
9.22.2 Qilu Pharmaceutical Major Business
9.22.3 Qilu Pharmaceutical Non-Opioid Pain Drug Product and Services
9.22.4 Qilu Pharmaceutical Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
9.22.5 Qilu Pharmaceutical Recent Developments/Updates
9.22.6 Qilu Pharmaceutical Competitive Strengths & Weaknesses
9.23 Yichang Humanwell Pharmaceutical
9.23.1 Yichang Humanwell Pharmaceutical Details
9.23.2 Yichang Humanwell Pharmaceutical Major Business
9.23.3 Yichang Humanwell Pharmaceutical Non-Opioid Pain Drug Product and Services
9.23.4 Yichang Humanwell Pharmaceutical Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
9.23.5 Yichang Humanwell Pharmaceutical Recent Developments/Updates
9.23.6 Yichang Humanwell Pharmaceutical Competitive Strengths & Weaknesses
9.24 Tongfang Pharma
9.24.1 Tongfang Pharma Details
9.24.2 Tongfang Pharma Major Business
9.24.3 Tongfang Pharma Non-Opioid Pain Drug Product and Services
9.24.4 Tongfang Pharma Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
9.24.5 Tongfang Pharma Recent Developments/Updates
9.24.6 Tongfang Pharma Competitive Strengths & Weaknesses
9.25 Fresenius
9.25.1 Fresenius Details
9.25.2 Fresenius Major Business
9.25.3 Fresenius Non-Opioid Pain Drug Product and Services
9.25.4 Fresenius Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
9.25.5 Fresenius Recent Developments/Updates
9.25.6 Fresenius Competitive Strengths & Weaknesses

+357 96 030922
info@marketpublishers.com

10 INDUSTRY CHAIN ANALYSIS

10.1 Non-Opioid Pain Drug Industry Chain
10.2 Non-Opioid Pain Drug Upstream Analysis
10.3 Non-Opioid Pain Drug Midstream Analysis
10.4 Non-Opioid Pain Drug Downstream Analysis

11 RESEARCH FINDINGS AND CONCLUSION

12 APPENDIX

12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

+357 96 030922
info@marketpublishers.com

List Of Tables

LIST OF TABLES

Table 1. World Non-Opioid Pain Drug Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Non-Opioid Pain Drug Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Non-Opioid Pain Drug Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Non-Opioid Pain Drug Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Non-Opioid Pain Drug Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Non-Opioid Pain Drug Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Non-Opioid Pain Drug Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Non-Opioid Pain Drug Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Non-Opioid Pain Drug Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Non-Opioid Pain Drug Players in 2025
Table 12. World Non-Opioid Pain Drug Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Non-Opioid Pain Drug Company Evaluation Quadrant
Table 14. Head Office of Key Non-Opioid Pain Drug Players
Table 15. Non-Opioid Pain Drug Market: Company Product Type Footprint
Table 16. Non-Opioid Pain Drug Market: Company Product Application Footprint
Table 17. Non-Opioid Pain Drug Mergers & Acquisitions Activity
Table 18. United States VS China Non-Opioid Pain Drug Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Non-Opioid Pain Drug Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Non-Opioid Pain Drug Companies, Headquarters (States, Country)
Table 21. United States Based Companies Non-Opioid Pain Drug Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Non-Opioid Pain Drug Revenue Market

+357 96 030922
info@marketpublishers.com

Share (2021-2026)
Table 23. China Based Non-Opioid Pain Drug Companies, Headquarters (Province, Country)
Table 24. China Based Companies Non-Opioid Pain Drug Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Non-Opioid Pain Drug Revenue Market Share (2021-2026)
Table 26. Rest of World Based Non-Opioid Pain Drug Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Non-Opioid Pain Drug Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Non-Opioid Pain Drug Revenue Market Share (2021-2026)
Table 29. World Non-Opioid Pain Drug Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Non-Opioid Pain Drug Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Non-Opioid Pain Drug Market Size by Type (2027-2032) & (USD Million)
Table 32. World Non-Opioid Pain Drug Market Size by Drug Ingredients, (USD Million), 2021 & 2025 & 2032
Table 33. World Non-Opioid Pain Drug Market Size Value by Drug Ingredients (2021-2026) & (USD Million)
Table 34. World Non-Opioid Pain Drug Market Size by Drug Ingredients (2027-2032) & (USD Million)
Table 35. World Non-Opioid Pain Drug Market Size by Route of Administration, (USD Million), 2021 & 2025 & 2032
Table 36. World Non-Opioid Pain Drug Market Size Value by Route of Administration (2021-2026) & (USD Million)
Table 37. World Non-Opioid Pain Drug Market Size by Route of Administration (2027-2032) & (USD Million)
Table 38. World Non-Opioid Pain Drug Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Non-Opioid Pain Drug Market Size by Application (2021-2026) & (USD Million)
Table 40. World Non-Opioid Pain Drug Market Size by Application (2027-2032) & (USD Million)
Table 41. Vertex Pharmaceuticals Basic Information, Manufacturing Base and Competitors

+357 96 030922
info@marketpublishers.com

Table 42. Vertex Pharmaceuticals Major Business
Table 43. Vertex Pharmaceuticals Non-Opioid Pain Drug Product and Services
Table 44. Vertex Pharmaceuticals Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Vertex Pharmaceuticals Recent Developments/Updates
Table 46. Vertex Pharmaceuticals Competitive Strengths & Weaknesses
Table 47. Kenvue Basic Information, Manufacturing Base and Competitors
Table 48. Kenvue Major Business
Table 49. Kenvue Non-Opioid Pain Drug Product and Services
Table 50. Kenvue Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Kenvue Recent Developments/Updates
Table 52. Kenvue Competitive Strengths & Weaknesses
Table 53. Haleon Basic Information, Manufacturing Base and Competitors
Table 54. Haleon Major Business
Table 55. Haleon Non-Opioid Pain Drug Product and Services
Table 56. Haleon Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Haleon Recent Developments/Updates
Table 58. Haleon Competitive Strengths & Weaknesses
Table 59. Bayer Basic Information, Manufacturing Base and Competitors
Table 60. Bayer Major Business
Table 61. Bayer Non-Opioid Pain Drug Product and Services
Table 62. Bayer Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Bayer Recent Developments/Updates
Table 64. Bayer Competitive Strengths & Weaknesses
Table 65. Pfizer Basic Information, Manufacturing Base and Competitors
Table 66. Pfizer Major Business
Table 67. Pfizer Non-Opioid Pain Drug Product and Services
Table 68. Pfizer Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. Pfizer Recent Developments/Updates
Table 70. Pfizer Competitive Strengths & Weaknesses
Table 71. Pacira BioSciences Basic Information, Manufacturing Base and Competitors
Table 72. Pacira BioSciences Major Business
Table 73. Pacira BioSciences Non-Opioid Pain Drug Product and Services
Table 74. Pacira BioSciences Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

+357 96 030922
info@marketpublishers.com

Table 75. Pacira BioSciences Recent Developments/Updates
Table 76. Pacira BioSciences Competitive Strengths & Weaknesses
Table 77. Heron Therapeutics Basic Information, Manufacturing Base and Competitors
Table 78. Heron Therapeutics Major Business
Table 79. Heron Therapeutics Non-Opioid Pain Drug Product and Services
Table 80. Heron Therapeutics Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Heron Therapeutics Recent Developments/Updates
Table 82. Heron Therapeutics Competitive Strengths & Weaknesses
Table 83. Scilex Holding Basic Information, Manufacturing Base and Competitors
Table 84. Scilex Holding Major Business
Table 85. Scilex Holding Non-Opioid Pain Drug Product and Services
Table 86. Scilex Holding Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Scilex Holding Recent Developments/Updates
Table 88. Scilex Holding Competitive Strengths & Weaknesses
Table 89. Grünenthal Basic Information, Manufacturing Base and Competitors
Table 90. Grünenthal Major Business
Table 91. Grünenthal Non-Opioid Pain Drug Product and Services
Table 92. Grünenthal Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Grünenthal Recent Developments/Updates
Table 94. Grünenthal Competitive Strengths & Weaknesses
Table 95. Hisamitsu Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 96. Hisamitsu Pharmaceutical Major Business
Table 97. Hisamitsu Pharmaceutical Non-Opioid Pain Drug Product and Services
Table 98. Hisamitsu Pharmaceutical Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. Hisamitsu Pharmaceutical Recent Developments/Updates
Table 100. Hisamitsu Pharmaceutical Competitive Strengths & Weaknesses
Table 101. Daiichi Sankyo Basic Information, Manufacturing Base and Competitors
Table 102. Daiichi Sankyo Major Business
Table 103. Daiichi Sankyo Non-Opioid Pain Drug Product and Services
Table 104. Daiichi Sankyo Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. Daiichi Sankyo Recent Developments/Updates
Table 106. Daiichi Sankyo Competitive Strengths & Weaknesses
Table 107. AFT Pharmaceuticals Basic Information, Manufacturing Base and

+357 96 030922
info@marketpublishers.com

Competitors
Table 108. AFT Pharmaceuticals Major Business
Table 109. AFT Pharmaceuticals Non-Opioid Pain Drug Product and Services
Table 110. AFT Pharmaceuticals Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. AFT Pharmaceuticals Recent Developments/Updates
Table 112. AFT Pharmaceuticals Competitive Strengths & Weaknesses
Table 113. Viatris Basic Information, Manufacturing Base and Competitors
Table 114. Viatris Major Business
Table 115. Viatris Non-Opioid Pain Drug Product and Services
Table 116. Viatris Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 117. Viatris Recent Developments/Updates
Table 118. Viatris Competitive Strengths & Weaknesses
Table 119. Teva Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 120. Teva Pharmaceutical Major Business
Table 121. Teva Pharmaceutical Non-Opioid Pain Drug Product and Services
Table 122. Teva Pharmaceutical Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 123. Teva Pharmaceutical Recent Developments/Updates
Table 124. Teva Pharmaceutical Competitive Strengths & Weaknesses
Table 125. Dr. Reddy's Basic Information, Manufacturing Base and Competitors
Table 126. Dr. Reddy's Major Business
Table 127. Dr. Reddy's Non-Opioid Pain Drug Product and Services
Table 128. Dr. Reddy's Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 129. Dr. Reddy's Recent Developments/Updates
Table 130. Dr. Reddy's Competitive Strengths & Weaknesses
Table 131. Sun Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 132. Sun Pharmaceutical Major Business
Table 133. Sun Pharmaceutical Non-Opioid Pain Drug Product and Services
Table 134. Sun Pharmaceutical Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 135. Sun Pharmaceutical Recent Developments/Updates
Table 136. Sun Pharmaceutical Competitive Strengths & Weaknesses
Table 137. Jiangsu Hengrui Basic Information, Manufacturing Base and Competitors
Table 138. Jiangsu Hengrui Major Business

+357 96 030922
info@marketpublishers.com

Table 139. Jiangsu Hengrui Non-Opioid Pain Drug Product and Services
Table 140. Jiangsu Hengrui Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 141. Jiangsu Hengrui Recent Developments/Updates
Table 142. Jiangsu Hengrui Competitive Strengths & Weaknesses
Table 143. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 144. Johnson & Johnson Major Business
Table 145. Johnson & Johnson Non-Opioid Pain Drug Product and Services
Table 146. Johnson & Johnson Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 147. Johnson & Johnson Recent Developments/Updates
Table 148. Johnson & Johnson Competitive Strengths & Weaknesses
Table 149. Hubei Hendi Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 150. Hubei Hendi Pharmaceutical Major Business
Table 151. Hubei Hendi Pharmaceutical Non-Opioid Pain Drug Product and Services
Table 152. Hubei Hendi Pharmaceutical Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 153. Hubei Hendi Pharmaceutical Recent Developments/Updates
Table 154. Hubei Hendi Pharmaceutical Competitive Strengths & Weaknesses
Table 155. CSPC Pharmaceutical Group Basic Information, Manufacturing Base and Competitors
Table 156. CSPC Pharmaceutical Group Major Business
Table 157. CSPC Pharmaceutical Group Non-Opioid Pain Drug Product and Services
Table 158. CSPC Pharmaceutical Group Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 159. CSPC Pharmaceutical Group Recent Developments/Updates
Table 160. CSPC Pharmaceutical Group Competitive Strengths & Weaknesses
Table 161. Simcere Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 162. Simcere Pharmaceutical Major Business
Table 163. Simcere Pharmaceutical Non-Opioid Pain Drug Product and Services
Table 164. Simcere Pharmaceutical Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 165. Simcere Pharmaceutical Recent Developments/Updates
Table 166. Simcere Pharmaceutical Competitive Strengths & Weaknesses
Table 167. Qilu Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 168. Qilu Pharmaceutical Major Business

+357 96 030922
info@marketpublishers.com

Table 169. Qilu Pharmaceutical Non-Opioid Pain Drug Product and Services
Table 170. Qilu Pharmaceutical Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 171. Qilu Pharmaceutical Recent Developments/Updates
Table 172. Qilu Pharmaceutical Competitive Strengths & Weaknesses
Table 173. Yichang Humanwell Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 174. Yichang Humanwell Pharmaceutical Major Business
Table 175. Yichang Humanwell Pharmaceutical Non-Opioid Pain Drug Product and Services
Table 176. Yichang Humanwell Pharmaceutical Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 177. Yichang Humanwell Pharmaceutical Recent Developments/Updates
Table 178. Yichang Humanwell Pharmaceutical Competitive Strengths & Weaknesses
Table 179. Tongfang Pharma Basic Information, Manufacturing Base and Competitors
Table 180. Tongfang Pharma Major Business
Table 181. Tongfang Pharma Non-Opioid Pain Drug Product and Services
Table 182. Tongfang Pharma Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 183. Tongfang Pharma Recent Developments/Updates
Table 184. Tongfang Pharma Competitive Strengths & Weaknesses
Table 185. Fresenius Basic Information, Manufacturing Base and Competitors
Table 186. Fresenius Major Business
Table 187. Fresenius Non-Opioid Pain Drug Product and Services
Table 188. Fresenius Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 189. Fresenius Recent Developments/Updates
Table 190. Fresenius Competitive Strengths & Weaknesses
Table 191. Global Key Players of Non-Opioid Pain Drug Upstream (Raw Materials)
Table 192. Global Non-Opioid Pain Drug Typical Customers

+357 96 030922
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

Figure 1. Non-Opioid Pain Drug Picture
Figure 2. World Non-Opioid Pain Drug Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Non-Opioid Pain Drug Total Revenue (2021-2032) & (USD Million)
Figure 4. World Non-Opioid Pain Drug Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Non-Opioid Pain Drug Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Non-Opioid Pain Drug Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Non-Opioid Pain Drug Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Non-Opioid Pain Drug Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Non-Opioid Pain Drug Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Non-Opioid Pain Drug Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Non-Opioid Pain Drug Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Non-Opioid Pain Drug Revenue (2021-2032) & (USD Million)
Figure 13. Non-Opioid Pain Drug Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Non-Opioid Pain Drug Consumption Value (2021-2032) & (USD Million)
Figure 16. World Non-Opioid Pain Drug Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Non-Opioid Pain Drug Consumption Value (2021-2032) & (USD Million)
Figure 18. China Non-Opioid Pain Drug Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Non-Opioid Pain Drug Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Non-Opioid Pain Drug Consumption Value (2021-2032) & (USD

+357 96 030922
info@marketpublishers.com

Million)
Figure 21. South Korea Non-Opioid Pain Drug Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Non-Opioid Pain Drug Consumption Value (2021-2032) & (USD Million)
Figure 23. India Non-Opioid Pain Drug Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Non-Opioid Pain Drug by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Non-Opioid Pain Drug Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Non-Opioid Pain Drug Markets in 2025
Figure 27. United States VS China: Non-Opioid Pain Drug Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Non-Opioid Pain Drug Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Non-Opioid Pain Drug Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Non-Opioid Pain Drug Market Size Market Share by Type in 2025
Figure 31. Acetaminophen/Paracetamol
Figure 32. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Figure 33. Selective COX-2 Inhibitors
Figure 34. Sodium Channel Pain Signal Inhibitors
Figure 35. Local Anesthetic Analgesics
Figure 36. Other
Figure 37. World Non-Opioid Pain Drug Market Size Market Share by Type (2021-2032)
Figure 38. World Non-Opioid Pain Drug Market Size by Drug Ingredients, (USD Million), 2021 & 2025 & 2032
Figure 39. World Non-Opioid Pain Drug Market Size Market Share by Drug Ingredients in 2025
Figure 40. Single-Agent Drugs
Figure 41. Combination Drugs
Figure 42. World Non-Opioid Pain Drug Market Size Market Share by Drug Ingredients (2021-2032)
Figure 43. World Non-Opioid Pain Drug Market Size by Route of Administration, (USD Million), 2021 & 2025 & 2032
Figure 44. World Non-Opioid Pain Drug Market Size Market Share by Route of Administration in 2025
Figure 45. Oral Drugs

+357 96 030922
info@marketpublishers.com

Figure 46. Injectable Drugs
Figure 47. Topical Drugs
Figure 48. World Non-Opioid Pain Drug Market Size Market Share by Route of Administration (2021-2032)
Figure 49. World Non-Opioid Pain Drug Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 50. World Non-Opioid Pain Drug Market Size Market Share by Application in 2025
Figure 51. Postoperative Pain
Figure 52. Musculoskeletal Pain
Figure 53. Arthritis Pain
Figure 54. Neuropathic Pain
Figure 55. Headache and Migraine
Figure 56. Other
Figure 57. World Non-Opioid Pain Drug Market Size Market Share by Application (2021-2032)
Figure 58. Non-Opioid Pain Drug Industrial Chain
Figure 59. Methodology
Figure 60. Research Process and Data Source

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Global Non-Opioid Pain Drug Supply, Demand and Key Producers, 2026-2032
Product link: https://marketpublishers.com/r/G2CE4C17E7D4EN.html
Price: US$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G2CE4C17E7D4EN.html